Most pharmaceutical products tolerate ambient room temperature without much fuss. A small but growing share don't. Biologics, mRNA vaccines, certain hormone therapies, specialty oncology, gene therapies, all of these have stability profiles that demand controlled temperature from the factory door to the patient's hand. The packaging side of that supply chain is its own discipline.
Which medicines actually need temperature control
Four broad categories:
Biologics. Monoclonal antibodies, insulin, recombinant proteins. Stability ranges typically 2-8 degrees Celsius. Excursion to room temperature can degrade the protein structure, sometimes irreversibly.
mRNA and viral vector vaccines. Some need -20 degrees, the most fragile need -70. The cold chain technology to ship these at scale was a pandemic-era innovation that's now standard.
Gene therapies and cell therapies. Often shipped frozen, with strict thaw protocols at the trial site or clinic. Custom cold chain logistics, not standard.
Hormone therapies and specialty oncology. Typically room-temperature stable for short periods, but require controlled storage to prevent degradation over months.
If your API doesn't fit one of these, you probably don't need temperature-controlled packaging. Most stable solid orals ship in standard blister packs at ambient temperature.
What temperature-controlled packaging looks like
Three approaches, increasing in cost and capability:
Passive insulated containers. Polystyrene or vacuum-insulated panels with phase change materials (PCM) or gel packs inside. Maintains target temperature for 24-72 hours depending on configuration. The standard for last-mile clinical and commercial distribution in EU.
Active refrigerated containers. Powered cooling, reefer trucks, refrigerated airfreight. For long-distance and high-value shipments where the cost of failure justifies the equipment.
Hybrid solutions with monitoring. Combine passive insulation with electronic temperature data loggers, GPS tracking, and continuous validation against the lane qualification profile.
Where the secondary pack fits
The secondary pack (the wallet, the carton, the kit) sits inside the temperature-controlled tertiary container. It doesn't need to be temperature-controlling itself. But it does need to be compatible with cold chain handling.
Cold seal blister wallets specifically sidestep one heat-related risk: the API never sees elevated temperature during pack assembly. Compare that to heat seal lines that briefly expose the pack to sealing temperature. For genuinely heat-sensitive APIs, that brief exposure can matter. Cold seal blister packaging avoids it entirely.
Where things go wrong in cold chain packaging
The most common failure mode isn't equipment, it's lane qualification. The pack performs perfectly in the test, then fails on a real shipment because:
- The route includes a 4-hour layover at a warm warehouse that wasn't in the validation.
- The destination market has summer ambient temperatures the test profile didn't account for.
- Customs delays add 24 hours of unrefrigerated transit.
- The receiving site stores the pack in a corridor over the weekend.
Robust lane qualification accounts for the worst case, not the average.
If you're scoping cold chain packaging
The conversation starts with the stability profile and the geography. From there we work through the secondary pack format, the tertiary configuration, and the cold chain partner. Send us the brief.
Request a free sample now!
